Initiation of Insulin Aspart in Type 2 Diabetes

Novo Nordisk

Status and phase: Completed; Phase 4

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin aspart

Study type: Interventional

Funder types: Industry

Identifiers

NCT00572806

ANA-1501

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.

Enrollment: 6 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes for at least 3 years
• HbA1c greater than 8.0%
• Body Mass Index (BMI) below 40.0 kg/m2
• Inadequate treatment with diet and OADs
• Never received treatment with insulin

Exclusion criteria

• Type 1 diabetes
• Known or suspected allergy to investigational product

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)